This can aid in monitoring the progression of Grade 1 carcinomas to higher grades which can further aid in deciding and reframing the treatment strategies according to the progression of EZH2 immunoexpression. However, Azizmohammadi et al. studied well / moderately differentiated (18/39, 46%) and poorly differentiated (21/39, 54%) cervical carcinomas and reported no significant correlation between EZH2 expression and different histological grades (p = 0.43) [24]. This evidence concerns the gene EZH2 and carcinoma.